Scarica l'app Stockscreener
25.48
2.17%
0.54
Dopo l'orario di chiusura:
25.48
Precedente Chiudi:
$24.94
Aprire:
$26.28
Volume 24 ore:
656.36K
Relative Volume:
0.60
Capitalizzazione di mercato:
$1.92B
Reddito:
$122.87M
Utile/perdita netta:
$-73.68M
Rapporto P/E:
-25.99
EPS:
-0.9803
Flusso di cassa netto:
$-39.27M
1 W Prestazione:
-4.53%
1M Prestazione:
+31.54%
6M Prestazione:
+94.50%
1 anno Prestazione:
+101.90%
Intervallo 1D:
$25.44
$26.46
Intervallo di 1 settimana:
$24.79
$27.49
Portata 52W:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
25.48 | 1.88B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Zymeworks (NYSE:ZYME) Shares Gap UpWhat's Next? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's What Happened - MarketBeat
EcoR1 Capital LLC Increases Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Zymeworks (ZYME) Receives Rating Upgrade and Increased Price Tar - GuruFocus
Redmile Group LLC Sells 638,318 Shares of Zymeworks Inc. $ZYME - MarketBeat
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Delta Optimist
Norges Bank Buys New Shares in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks to Engage in Key Investor Conferences - MSN
Zymeworks (ZYME) Is Up 5.2% After First FDA Approval For Zanidatamab And Royalty ShiftHas The Bull Case Changed? - Sahm
Zymeworks (ZYME): Reassessing Valuation After FDA Zanidatamab Approval and a Sharp Share Price Rally - Sahm
Zymeworks Inc Stock Analysis and ForecastPrice Momentum Alerts & Low Entry Investment Plans - earlytimes.in
How higher bond yields impact Zymeworks Inc. (ZA8) stockPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsPortfolio Value Report & Long Hold Capital Preservation Tips - Newser
What technical patterns form on Zymeworks Inc. (ZA8) stock chartsWeekly Gains Summary & Short-Term Swing Trade Alerts - Newser
Is Zymeworks Inc. (ZA8) stock considered safe havenInsider Selling & AI Powered Market Trend Analysis - Newser
Will Zymeworks Inc. (ZA8) stock maintain strong growth2025 Earnings Impact & Safe Capital Allocation Plans - Newser
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
Citizens Initiates Coverage of Zymeworks (ZYME) with Market Outperform Recommendation - Nasdaq
How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Gainers & Verified Technical Signals - Newser
Zymeworks Announces Participation in Upcoming Conferences - The Manila Times
Zymeworks Inc. Announces Participation in ASCO GI and J.P. Morgan Healthcare Conference, Highlighting Advances in HER2-Driven Gastrointestinal Cancers and Novel Drug Developments - Quiver Quantitative
Is Zymeworks Inc. (ZA8) stock supported by strong fundamentalsAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN
Is Zymeworks Inc a good long term investmentMarket Capitalization Trends & Join a Community of Smart Investors - earlytimes.in
Zymeworks Inc. $ZYME Stock Position Lifted by Tejara Capital Ltd - MarketBeat
Zymeworks (ZYME) Is Up 13.8% After Positive Zanidatamab Trial and Share Buyback PlanWhat's Changed - simplywall.st
Zymeworks (NASDAQ:ZYME) Stock Price Up 8%Time to Buy? - MarketBeat
Zymeworks (NYSE:ZYME) Trading Up 6.1%Here's Why - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Zymeworks (NYSE:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
A Look at Zymeworks (ZYME) Valuation Following $125M Buyback and Positive Zanidatamab Phase 3 Results - Sahm
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN
Zymeworks stock hits 52-week high at 26.2 USD By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Sees Large Volume IncreaseHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 26.2 USD - Investing.com
Zymeworks Inc.Common Stock (Nasdaq:ZYME) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Zymeworks Announces Participation in Upcoming Investor Conferences - lelezard.com
Shareholder Miller Files To Sell 118,000 Of Zymeworks Inc [ZYME] - TradingView
Hillsdale Investment Management Inc. Lowers Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. Management to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
Zymeworks (NASDAQ: ZYME) to Join Evercore, Citi 2025 Healthcare Conferences - Stock Titan
Zymeworks wanted to be Canada’s first Big Pharma. Despite two blockbusters-in-the-making, that’s no longer the plan - The Globe and Mail
Zymeworks Inc. (NASDAQ:ZYME) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):